| Literature DB >> 22373425 |
Yun Ju Sung1, Treva K Rice, Dabeeru C Rao.
Abstract
Genetic Analysis Workshop 17 used real sequence data from the 1000 Genomes Project and simulated phenotypes influenced by a large number of rare variants. Our aim is to evaluate the performance of various collapsing methods that were developed for analysis of multiple rare variants. We apply collapsing methods to continuous phenotypes Q1 and Q2 for all 200 replicates of the unrelated individuals data. Within each gene, we collapse (1) all SNPs, (2) all SNPs with minor allele frequency (MAF) < 0.05, and (3) nonsynonymous SNPs with MAF < 0.05. We consider two tests when collapsing variants: using the proportion of variants and using the presence/absence of any variant. We also compare our results to a single-marker analysis using PLINK. For phenotype Q1, the proportion test for collapsing rare nonsynonymous SNPs often performed the best. Two genes (FLT1 and KDR) had statistically significant results. A single-marker analysis using PLINK also provided statistically significant results for some SNPs within these two genes. For phenotype Q2, collapsing rare nonsynonymous SNPs performed the best, with almost no difference between proportion and presence tests. However, neither collapsing methods nor a single-marker analysis provided statistically significant results at the true genes for Q2. We also found that a large number of noncausal genes had high correlations with causal genes for Q1 and Q2, which may account for inflated false positives.Entities:
Year: 2011 PMID: 22373425 PMCID: PMC3287846 DOI: 10.1186/1753-6561-5-S9-S121
Source DB: PubMed Journal: BMC Proc ISSN: 1753-6561
Figure 1ROC curves of collapsing methods for Q1 and Q2. The y-axis shows power (true-positive rate) and the x-axis shows type I error rate (false-positive rate) for significance level between 0 and 1. Prop is the proportion test; Y/N is the presence test.
Averaged −log(P) across 200 replicates from collapsing methods for Q1 and Q2 at the true causal genes
| Gene | All SNPs | Rare SNPs | Rare nonsynonymous SNPs | Best single | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Prop | Y/N | Prop | Y/N | Prop | Y/N | |||||
| Q1 | ||||||||||
| 18 (5) | 0.45 | 0.40 | 17 | 1.88 | 1.88 | 9 | 2.24 | 2.50 | 3.94 | |
| 10 (2) | 2.38 | 8 | 0.85 | 0.85 | 4 | 0.76 | 0.76 | 2.28 | ||
| 35 (11) | 6.61 | 2.59 | 32 | 9.70 | 6.84 | 19 | 15.04 | 24.26 | ||
| 10 (2) | 2.70 | 2.98 | 10 | 2.70 | 5 | 1.44 | 1.50 | 1.77 | ||
| 8 (4) | 3.03 | 3.31 | 8 | 3.03 | 3.31 | 6 | 3.24 | 3.39 | ||
| 21 (3) | 0.37 | 17 | 0.34 | 0.36 | 8 | 0.55 | 0.58 | 1.02 | ||
| 16 (10) | 8.78 | 3.84 | 15 | 8.24 | 8.18 | 10 | 8.10 | 5.63 | ||
| 6 (1) | 1.47 | 1.64 | 6 | 1.47 | 2 | 0.87 | 0.87 | 1.21 | ||
| Q2 | ||||||||||
| 29 (13) | 0.71 | 0.57 | 28 | 1.22 | 1.43 | 25 | 1.32 | 1.59 | 1.58 | |
| 5 (3) | 0.53 | 0.50 | 5 | 0.50 | 4 | 0.39 | 0.39 | 0.57 | ||
| 20 (3) | 0.37 | 0.37 | 17 | 0.64 | 0.63 | 8 | 1.27 | 1.88 | ||
| 11 (4) | 0.44 | 0.50 | 9 | 0.72 | 0.94 | 7 | 1.66 | 1.81 | ||
| 29 (8) | 0.41 | 0.37 | 27 | 0.42 | 0.46 | 11 | 0.86 | 0.95 | ||
| 11 (2) | 0.66 | 0.62 | 11 | 0.66 | 0.62 | 3 | 1.26 | 1.22 | ||
| 24 (9) | 1.25 | 23 | 1.60 | 1.04 | 14 | 1.34 | 1.20 | 2.03 | ||
| 24 (10) | 0.52 | 0.89 | 23 | 0.87 | 18 | 0.80 | 0.76 | 1.12 | ||
| 27 (8) | 0.41 | 0.40 | 24 | 0.65 | 0.61 | 15 | 1.22 | 0.83 | ||
| 7 (2) | 2.90 | 6 | 0.37 | 0.46 | 2 | 0.96 | 0.96 | 3.42 | ||
| 15 (7) | 0.80 | 12 | 0.94 | 0.91 | 9 | 1.03 | 1.01 | 2.08 | ||
| 8 (2) | 0.89 | 0.54 | 8 | 0.54 | 4 | 0.75 | 0.59 | 0.90 | ||
Boldface indicates the best result among the collapsing methods for each gene. Rare SNPs are defined as SNPs with MAF < 0.05. Prop is the proportion test; Y/N is the presence test. “Best Single” is the best signal from a single-marker analysis among all SNPs within each gene.
Figure 2Manhattan plots for Q1 and Q2 using the first replicate from the single-marker analysis using PLINK. The x-axis represents chromosomes 1 through 22, and the y-axis is the −log(P) value for the association test. The black circles indicate the true causal SNPs.